SummerHaven Investment Management’s Catalyst Pharmaceutical CPRX Stock Holding History

SummerHaven Investment Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-93,156	Closed	-$1.25M	–	213
2023 Q2	$1.25M	Sell	93,156 -7,436	-7%	-$107K	0.8%	20
2023 Q1	$1.67M	Buy	100,592 +1,029	+1%	+$17K	0.97%	4
2022 Q4	$1.85M	Buy	99,563 +723	+0.7%	+$11.1K	1.1%	2
2022 Q3	$1.27M	Sell	98,840 -59,633	-38%	-$707K	0.88%	2
2022 Q2	$1.11M	Hold	158,473	–	–	0.75%	23
2022 Q1	$1.31M	Buy	158,473 +7,089	+5%	+$50.1K	0.74%	17
2021 Q4	$1.02M	Hold	151,384	–	–	0.55%	55
2021 Q3	$802K	Buy	+151,384	New	+$828K	0.47%	137

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SummerHaven Investment Management's CPRX Position: Q3 2023 in Review

SummerHaven Investment Management sold out of Catalyst Pharmaceutical (CPRX) in Q3 2023, closing a stake of 93,156 shares — an estimated $1.25M sold.

SummerHaven Investment Management first reported a position in CPRX in Q3 2021 and held it in 8 quarters. The position peaked at $1.85M in Q4 2022. 255 funds tracked by Wall St. Rank hold CPRX as of Q3 2023.

SummerHaven Investment Management reported no remaining Catalyst Pharmaceutical position as of Q3 2023 after selling out during the quarter.
SummerHaven Investment Management sold 93,156 Catalyst Pharmaceutical shares in Q3 2023, an estimated $1.25M.
SummerHaven Investment Management first reported a position in Catalyst Pharmaceutical in Q3 2021 and held it in 8 quarters.
SummerHaven Investment Management's Catalyst Pharmaceutical position peaked at $1.85M in Q4 2022.
255 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2023.

Based on SummerHaven Investment Management's 13F filing for Q3 2023, filed 13 Oct 2023.